HomeNewsGlobal Pharma

Zydus Gets Tentative Approval from USFDA for Azilsartan Medoxomil Tablets

Zydus Gets Tentative Approval from USFDA for Azilsartan Medoxomil Tablets

Zydus Lifesciences Ltd. has secured a tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil Tablets, 40 mg and 80 mg (USRLD: Edarbi tablets).

Azilsartan is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Azilsartan medoxomil tablets may be used either alone or in combination with other antihypertensive agents. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India.

Azilsartan Medoxomil Tablets had annual sales of USD 89 mn in the United States. The group now has 398 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The group employs 26,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. Zydus has been actively discovering and developing New Chemical Entities (NCEs) novel biologicals, several biosimilars and vaccines as a part of its innovation pipeline.

More news about: global pharma | Published by Aishwarya | July - 06 - 2024 | 215

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members